SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.08-2.9%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (10531)2/20/2004 2:40:21 PM
From: Icebrg  Read Replies (1) of 52153
 
Cell Genesys

7:49 pm Cell Genesys confirms publication of GVAX paper (CEGE) 14.28 +1.41: -- Update -- Co confirms that a press release issued yesterday by Baylor University concerned data from the initial Phase 1/2 clinical trial of Cell Genesys' GVAX lung cancer vaccine trial. The data, which were published in the Feb 18, 2004 issue of the Journal of the National Cancer Institute, were previously presented in Dec 2002 at the International Conference on Gene Therapy of Cancer... see 09:04 and 08:13 updates for related commentary.

Sometimes it takes time for the markets to take notice. As the above snip notes, this is not really new news although the publishing takes place now. More or less the same data was presented in a PR from CEGE December 16, 2002.

Erik

cellgenesys.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News